GABA Therapeutics was founded with the core mission of developing innovative treatments for anxiety, depression, and chronic pain that are fast-acting, safe, and non-addictive. The company’s flagship product, GRX-917, leverages the production of endogenous neurosteroids and inhibits NLRP3 inflammation to offer a transformative solution for neuropsychiatric, neurological, and autoimmune disorders. GABA Therapeutics aims to address the unmet needs in mental health treatment with minimal side effects and no addiction potential.
Notable figures affiliated with GABA Therapeutics include Richard Farrell. The company has achieved significant milestones, including preparing GRX-917 for Phase 3 registration studies in anxiety. By focusing on mechanisms that induce natural neurosteroid production, GABA Therapeutics has made a substantial impact in the field of mental health, offering hope for safer and more effective treatments for anxiety and depression.
